Solid Tumor

A multicentre, open-label, randomised, Phase 2 study to compare the efficacy and safety of lenvatinib (LEN) in combination with ifosfamide (IFO) and etoposide (ETO) versus IFO and ETO in subjects from 5 years to <18 years (and adults) with relapsed or refractory osteosarcoma who have been treated with 1 prior chemotherapy regimen

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Single- Agent Ponatinib for the Treatment of advanced Leukemias or Solid Tumors in Pediatric Participants

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

A Phase 1b, Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (triplet escalation) and Abemaciclib in combination with Temozolomidea

A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma

FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma